June 25, 2026 · Blood · DOI: 10.1182/blood.2025031693

NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab

Listen to this summary

The authors investigate the role of the NG2-ITGA4 signaling axis in the aggressiveness of KMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2A-r B-ALL), a subtype associated with poor prognosis and high relapse rates. They demonstrate that NG2 promotes cell proliferation and migration through Rho GTPase activity in an ITGA4-dependent manner, and show that targeting ITGA4 with natalizumab can delay leukemia progression and enhance chemotherapy efficacy in patient-derived models. This study highlights a potential therapeutic strategy for improving outcomes in KMT2A-r B-ALL patients.

Alba Rubio-Gayarre, Meritxell Vinyoles, Juan Ramón Tejedor, Mercedes Guerrero-Murillo, Narcís Fernandez-Fuentes, Rita Caracuel-Peramos, Maria Carmen Plaza-Calonge, Alba Martinez-Moreno, Heleia Roca-Ho, Paolo Petazzi, Alba Pañella-Alférez, Angela Meseguer-Giron, Kirsten S Vrenken, Mario F Fraga, Pilar Leoz Allegretti, Carlos Palacio-Garcia, Pablo Velasco, José Luis Fuster, Ronald W Stam, Juan Carlos Rodríguez-Manzaneque, Xose R Bustelo, Javier Robles-Valero, Pablo Menendez, Clara Bueno, Belén Lopez-Millan

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play